The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Primo N. Lara

University of California

Davis Cancer Center

4501 X St

Suite 3016

[email]@*.ucdavis.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of California, Davis Cancer Center, 4501 X St, Suite 3016. 2000 - 2011
  • University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA. 2006

References

  1. Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer. Lara, P.N., Douillard, J.Y., Nakagawa, K., von Pawel, J., McKeage, M.J., Albert, I., Losonczy, G., Reck, M., Heo, D.S., Fan, X., Fandi, A., Scagliotti, G. J. Clin. Oncol. (2011) [Pubmed]
  2. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Lara, P.N., Longmate, J., Reckamp, K., Gitlitz, B., Argiris, A., Ramalingam, S., Belani, C.P., Mack, P.C., Lau, D.H., Koczywas, M., Wright, J.J., Shepherd, F.A., Leighl, N., Gandara, D.R. Clin. Lung. Cancer (2011) [Pubmed]
  3. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Lara, P.N., Chansky, K., Shibata, T., Fukuda, H., Tamura, T., Crowley, J., Redman, M.W., Natale, R., Saijo, N., Gandara, D.R. Cancer (2010) [Pubmed]
  4. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. Lara, P.N., Natale, R., Crowley, J., Lenz, H.J., Redman, M.W., Carleton, J.E., Jett, J., Langer, C.J., Kuebler, J.P., Dakhil, S.R., Chansky, K., Gandara, D.R. J. Clin. Oncol. (2009) [Pubmed]
  5. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Lara, P.N., Longmate, J., Evans, C.P., Quinn, D.I., Twardowski, P., Chatta, G., Posadas, E., Stadler, W., Gandara, D.R. Anticancer. Drugs (2009) [Pubmed]
  6. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. Lara, P.N., Redman, M.W., Kelly, K., Edelman, M.J., Williamson, S.K., Crowley, J.J., Gandara, D.R. J. Clin. Oncol. (2008) [Pubmed]
  7. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). Lara, P.N., Chansky, K., Davies, A.M., Franklin, W.A., Gumerlock, P.H., Guaglianone, P.P., Atkins, J.N., Farneth, N., Mack, P.C., Crowley, J.J., Gandara, D.R. J. Thorac. Oncol (2006) [Pubmed]
  8. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. Lara, P.N., Koczywas, M., Quinn, D.I., Lenz, H.J., Davies, A.M., Lau, D.H., Gumerlock, P.H., Longmate, J., Doroshow, J.H., Schenkein, D., Kashala, O., Gandara, D.R. J. Thorac. Oncol (2006) [Pubmed]
  9. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Lara, P.N., Stadler, W.M., Longmate, J., Quinn, D.I., Wexler, J., Van Loan, M., Twardowski, P., Gumerlock, P.H., Vogelzang, N.J., Vokes, E.E., Lenz, H.J., Doroshow, J.H., Gandara, D.R. Clin. Cancer Res. (2006) [Pubmed]
  10. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Lara, P.N., Gandara, D.R., Natale, R.B. Clin. Lung. Cancer (2006) [Pubmed]
  11. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Lara, P.N., Law, L.Y., Wright, J.J., Frankel, P., Twardowski, P., Lenz, H.J., Lau, D.H., Kawaguchi, T., Gumerlock, P.H., Doroshow, J.H., Gandara, D.R. Anticancer. Drugs (2005) [Pubmed]
  12. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Lara, P.N., Mack, P.C., Synold, T., Frankel, P., Longmate, J., Gumerlock, P.H., Doroshow, J.H., Gandara, D.R. Clin. Cancer Res. (2005) [Pubmed]
  13. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Lara, P.N., Bold, R.J., Mack, P.C., Davies, A.M., Gumerlock, P.H., Gandara, D.R. Clin. Lung. Cancer (2005) [Pubmed]
  14. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. Lara, P.N., Paterniti, D.A., Chiechi, C., Turrell, C., Morain, C., Horan, N., Montell, L., Gonzalez, J., Davis, S., Umutyan, A., Martel, C.L., Gandara, D.R., Wun, T., Beckett, L.A., Chen, M.S. J. Clin. Oncol. (2005) [Pubmed]
  15. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Lara, P.N., Meyers, F.J., Law, L.Y., Dawson, N.A., Houston, J., Lauder, I., Edelman, M.J. Cancer (2004) [Pubmed]
  16. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Lara, P.N., Laptalo, L., Longmate, J., Lau, D.H., Gandour-Edwards, R., Gumerlock, P.H., Doroshow, J.H., Gandara, D.R. Clin. Lung. Cancer (2004) [Pubmed]
  17. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Lara, P.N., Chee, K.G., Longmate, J., Ruel, C., Meyers, F.J., Gray, C.R., Edwards, R.G., Gumerlock, P.H., Twardowski, P., Doroshow, J.H., Gandara, D.R. Cancer (2004) [Pubmed]
  18. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Lara, P.N., Gumerlock, P.H., Mack, P.C., Lau, D.H., Gandour-Edwards, R., Edelman, M.J., Albain, K.S., Law, L.Y., Longmate, J., Frankel, P., Reddy, G.P., Israel, V., Doroshow, J.H., Gandara, D.R. Clin. Lung. Cancer (2004) [Pubmed]
  19. Angiogenesis-targeted therapies in prostate cancer. Lara, P.N., Twardowski, P., Quinn, D.I. Clin. Prostate. Cancer (2004) [Pubmed]
  20. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Lara, P.N., Frankel, P., Mack, P.C., Gumerlock, P.H., Galvin, I., Martel, C.L., Longmate, J., Doroshow, J.H., Lenz, H.J., Lau, D.H., Gandara, D.R. Clin. Cancer Res. (2003) [Pubmed]
  21. Non-small-cell lung cancer progression after first-line chemotherapy. Lara, P.N., Lau, D.H., Gandara, D.R. Curr. Treat. Options. Oncol (2002) [Pubmed]
  22. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Lara, P.N., Meyers, F.J., Gray, C.R., Edwards, R.G., Gumerlock, P.H., Kauderer, C., Tichauer, G., Twardowski, P., Doroshow, J.H., Gandara, D.R. Cancer (2002) [Pubmed]
  23. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. Lara, P.N., Higdon, R., Lim, N., Kwan, K., Tanaka, M., Lau, D.H., Wun, T., Welborn, J., Meyers, F.J., Christensen, S., O'Donnell, R., Richman, C., Scudder, S.A., Tuscano, J., Gandara, D.R., Lam, K.S. J. Clin. Oncol. (2001) [Pubmed]
  24. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Lara, P.N., Gandara, D.R., Longmate, J., Gumerlock, P.H., Lau, D.H., Edelman, M.J., Gandour-Edwards, R., Mack, P.C., Israel, V., Raschko, J., Frankel, P., Perez, E.A., Lenz, H.J., Doroshow, J.H. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  25. Malignant thymoma: current status and future directions. Lara, P.N. Cancer Treat. Rev. (2000) [Pubmed]
 
WikiGenes - Universities